by
According to the Foreclaro Global Research, the
Global
Plasmid DNA Manufacturing Market size was valued at USD 967.3 million in 2024. The report “Global
Plasmid DNA Manufacturing Market Segmentation By Product Type (Clinical-Grade
Plasmid DNA, Research-Grade Plasmid DNA, GMP-Grade Plasmid DNA), By Application
(Gene Therapy {Viral Vector Production, Non-Viral Gene Therapy}, Cell Therapy {CAR-T
Cell Therapy, TCR Cell Therapy}, Vaccine Development {DNA Vaccines, mRNA
Vaccine Production}, Research Applications {Protein Expression, CRISPR/Cas9
Gene Editing, Functional Genomics
Studies}), By End User (Pharmaceutical & Biotechnology Companies, Contract
Development and Manufacturing Organizations (CDMOs), Academic & Research Institutes,
Government Agencies), By Process Type (Stainless Steel Bioreactor-Based
Manufacturing, Single-Use Bioreactor-Based Manufacturing, Microbial
Fermentation, Purification Methods {Chromatography, Filtration}), By Scale of
Operation (Preclinical/Research Scale, Clinical Scale (Phase I-III), Commercial
Scale)- Industry Trends
and Forecast to 2033”
gives a detailed insight into current market dynamics and provides analysis on
future market growth.
The plasmid DNA (pDNA) production market is
growing rapidly, driven by the increasing resource of the use of its vital
feature in the production of advanced treatments, vaccines, and research
applications. Plasmid DNA serves as an important raw material for viral vector
production, non-viral gene treatments, cell-based absolute treatments, including
CAR-T and TCR, and DNA or mRNA vaccines. The surge in gene treatment pipelines,
the developing adoption of DNA and RNA-based vaccines post-COVID-19, and the developing
investment in oncology and unusual disorder research are fueling demand.
Technological innovations, together with single-use bioprocessing systems,
automation, and artificial biology, are improving scalability, purity, and
price efficiency. Moreover, pharmaceutical groups and CDMOs are increasing
their GMP-grade plasmid DNA capacities to fulfill stringent regulatory
necessities for medical and business use. Despite demanding situations
including excessive production costs, complicated downstream processing, and
dependence on professional expertise, the marketplace holds sturdy boom
potential, in particular in rising biotech areas and customized medicinal drug
applications.
Have any questions or need more information?
Click the link below to request a sample or make an inquiry before making your
purchase:
https://foreclaroglobalresearch.com/research-report/global-plasmid-dna-manufacturing-market
Global Plasmid
DNA Manufacturing Market Report Highlights
· Growing
use of plasmid DNA in gene therapy, mobileular therapy, and vaccine improvement
is a primary marketplace driver.
· Increasing
regulatory necessities and scientific packages are accelerating the demand for
GMP-compliant plasmid DNA.
· Adoption
of single-use systems, automation, and artificial biology equipment is
enhancing scalability, purity, and efficiency.
· Contract
improvement and production agencies are gaining prominence, imparting give-up-to-give-up
pDNA offerings to biotech and pharma companies
· North
America leads with sturdy biopharma infrastructure, even as Asia-Pacific
suggests the quickest increase because of investments and scientific studies.
· High
production costs, complicated downstream processing, regulatory hurdles, and
confined international delivery ability continue to be key bottlenecks.
Foreclaro
Global Research has segmented the Plasmid DNA Manufacturing Market report based
on Product Type, Application, End User, Process Type, Scale of Operation and
region:
Plasmid DNA Manufacturing Market, Product Type
Outlook (Revenue - USD Million, 2020 - 2033)
Clinical-Grade Plasmid DNA
Research-Grade Plasmid DNA
GMP-Grade Plasmid DNA
Plasmid DNA Manufacturing Market, Application
Outlook (Revenue - USD Million, 2020 - 2033)
Gene Therapy
·
Viral
Vector Production
·
Non-Viral
Gene Therapy
Cell Therapy
·
CAR-T
Cell Therapy
·
TCR
Cell Therapy
Vaccine Development
·
DNA
Vaccines
·
mRNA
Vaccine Production
Research Applications
·
Protein
Expression
·
CRISPR/Cas9
Gene Editing
·
Functional
Genomics Studies
Plasmid DNA Manufacturing Market, End
User Outlook (Revenue - USD Million, 2020 - 2033)
Pharmaceutical & Biotechnology Companies
Contract Development and Manufacturing
Organizations (CDMOs)
Academic & Research Institutes
Government Agencies
Plasmid DNA Manufacturing Market, Process
Type Outlook (Revenue - USD Million, 2020 - 2033)
Stainless Steel Bioreactor-Based Manufacturing
Single-Use Bioreactor-Based Manufacturing
Microbial Fermentation
Purification Methods
·
Chromatography
·
Filtration
Plasmid DNA Manufacturing Market, Scale
of Operation Outlook (Revenue - USD Million, 2020 - 2033)
Preclinical/Research Scale
Clinical Scale (Phase I-III)
Commercial Scale
Plasmid DNA Manufacturing Market,
Regional Outlook (Revenue - USD Million, 2020 - 2033)
North
America
·
United
States
·
Canada
·
Mexico
Europe
·
United
Kingdom
·
Germany
·
France
·
Spain
·
Italy
·
Rest
of Europe
Asia
Pacific
·
China
·
India
·
Japan
·
Australia
·
South
Korea
·
Rest
of Asia Pacific
Latin
America
·
Brazil
·
Argentina
·
Rest
of Latin America
Middle East
& Africa
·
Saudi
Arabia
·
South
Africa
·
Rest
of MEA
Global Plasmid DNA Manufacturing Market Key Players
·
Akron Biotech
·
Charles River Laboratories
·
VGXI, Inc.
·
Danaher (Aldevron)
·
Kaneka Corp.
·
Nature Technology
·
Cell and Gene Therapy Catapult
·
Eurofins Genomics
·
Lonza
·
Luminous BioSciences, LLC
